Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and
A*ccelerate Technologies Pte Ltd, the enterprise office of the
Agency for Science, Technology and Research (A*STAR), have signed a
USD$90 million agreement to co-create local deep tech start-ups in
the healthcare and life sciences sector. This agreement, is the
latest in a series of venture co-creation (VCC) agreements signed
by A*ccelerate to strengthen the start-up ecosystem in
Singapore.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190424005535/en/
(Photo: Business Wire)
Through this agreement, Aptorum Group and A*ccelerate are
looking at creating up to 20 deep tech ventures in Singapore over
the next five years. These enterprises will leverage technologies
co-developed by A*STAR research institutes and Aptorum Group. As
part of this agreement, the parties involved will also support the
start-ups’ growth through actively nurturing the entrepreneurs.
This will be done by connecting them to the relevant market
partners, and clients, using Aptorum Group’s worldwide network.
The key focus area in this initiative would be the healthcare
and life sciences sector. One of the areas both parties are looking
into is the translation of A*STAR’s capabilities in medical image
analytics and augmented reality, into real-time 2D and 3D magnetic
resonance imaging (MRI) surgical imaging solutions for applications
in the field of surgical robotics. This solution would empower
healthcare providers in Singapore, the region and globally with
more accurate imaging of their patients.
Aptorum Group and Aeneas Capital will also be launching an up to
USD$200 million healthcare and life science strategic investment
fund. This fund could be used to invest into the local biotech
ecosystem, and bring about greater vibrancy to the Singapore
economy. Aptorum Group and Aeneas Capital will also make
acquisitions in identified technologies and businesses
globally.
“This agreement is testament to the vibrancy of Singapore’s
biotech ecosystem, as well as the private sector’s confidence in
A*STAR’s capabilities in deep tech and biomedical research,” said
Mr Philip Lim, CEO of A*ccelerate. “Aptorum Group’s focus on
creating value in diagnostics, surgical robotics and therapeutics
through technological innovation makes them an ideal partner for
us. We look forward to co-creating local start-ups that will push
the boundaries of healthcare innovation and strengthen Singapore’s
future economy.”
Founder and CEO of Aptorum Group and Founder of Aeneas Capital
Mr. Ian Huen commented: “Aptorum’s vision is to advance the quality
of human life and patient care by facilitating the development of
medical and life science innovations. Our collaboration with A*STAR
A*ccelerate as Venture Co-Creation partner is very exciting,
allowing us to access and develop the excellent expertise and
technological ecosystems in Singapore through a strong partner such
as A*STAR and to strengthen the links between research, innovation
and enterprise. We strongly believe that the partnership will
undoubtedly yield a number of strong venture businesses that will
be eventually recognised worldwide and further catapult Singapore
as a core global player for technological advancements and
commercialisation hub.”
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing a broad range of
therapeutic and diagnostic technologies to tackle unmet medical
needs. The company is pursuing therapeutic and diagnostic projects
in neurology, infectious diseases, gastroenterology, oncology and
other disease areas, as well as non-therapeutic areas such as
surgical robotics and medical clinic in Hong Kong (Talem Medical)
with the initial focus on treatment of chronic diseases resulting
from modern sedentary lifestyles and aging population.
For more information about the Company, please visit
www.aptorumgroup.com.
About Aeneas Capital Limited
Aeneas Capital, a subsidiary of Aeneas Group Limited, is a
multi-disciplinary digital focused financial institution with cross
border capabilities and technology services. Aeneas Capital Limited
is regulated by the Hong Kong Securities & Futures Commission
in respect of investment management, securities brokerage and
investment advisory activities in Hong Kong. Aeneas Capital
businesses span across a broad range of investment products and
regions, servicing a vast array of professional investors,
institutions and corporate clients.
For more information on Aeneas Group, please visit
www.aeneasgroup.com.
About the Agency for Science, Technology and Research
(A*STAR)
The Agency for Science, Technology and Research (A*STAR) is
Singapore's lead public sector agency that spearheads economic
oriented research to advance scientific discovery and develop
innovative technology. Through open innovation, we collaborate with
our partners in both the public and private sectors to benefit
society.
As a Science and Technology Organisation, A*STAR bridges the gap
between academia and industry. Our research creates economic growth
and jobs for Singapore, and enhances lives by contributing to
societal benefits such as improving outcomes in healthcare, urban
living, and sustainability.
We play a key role in nurturing and developing a diversity of
talent and leaders in our Agency and research entities, the wider
research community and industry. A*STAR’s R&D activities span
biomedical sciences and physical sciences and engineering, with
research entities primarily located in Biopolis and
Fusionopolis.
For ongoing news, visit www.a-star.edu.sg.
About A*ccelerate Technologies Pte Limited
A*ccelerate is the commercialisation arm of the Agency for
Science, Technology and Research (A*STAR), Singapore’s lead agency
for fostering world-class scientific research and talent. As a
one-stop resource, A*ccelerate supports A*STAR in transforming the
economy through driving innovation and commercialising its research
outcomes.
Also known as Accelerate Technologies Pte Ltd, A*ccelerate
enhances the research output of A*STAR scientists by translating
and accelerating their inventions and intellectual capital into
marketable products, processes and services. Through shaping and
facilitating licensing deals and spin-offs, A*ccelerate actively
engages industry leaders and players to commercialise A*STAR’s
technologies and apply them to building ecosystems that benefit
business, industry and economy.
Forward-Looking Statements
This press release includes statements concerning Aptorum
Group Limited, Aeneas Capital Limited and its future expectations,
plans and prospects that constitute “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. For this purpose, any statements contained herein that are
not statements of historical fact may be deemed to be
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “target,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential,” or “continue,” or the negative of these terms or other
similar expressions. Aptorum Group and Aeneas
Capital have based these forward-looking statements largely on
its current expectations and projections about future events and
trends that it believes may affect its business, financial
condition and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions
including, without limitation, risks related to its announced
management and organizational changes, the continued service and
availability of key personnel, its ability to expand its product
assortments by offering additional products for additional consumer
segments, the company’s anticipated growth strategies, anticipated
trends and challenges in its business, and its expectations
regarding, and the stability of, its supply chain, and the risks
more fully described in Aptorum Group’s Form 20-F filed with the
SEC and other filings that Aptorum Group may make
with the SEC in the future. Aptorum Group and
Aeneas Capital assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190424005535/en/
Enquiries:For Aptorum Group LimitedContactInvestor
Relations and MediaTel: +852 2117 6611Email:
investor.relations@aptorumgroup.comWebsite:
http://www.aptorumgroup.comFor Aeneas Capital
LimitedContactInvestor Relations and MediaTel: +852 3469
7988Email: ir@aeneasgroup.comWebsite:
http://www.aeneasgroup.comFor A*STARDerrick Reginald
WongSenior Officer, Corporate CommunicationsAgency for Science,
Technology and ResearchTel: +65 6517 7970HP: +65 9639 9900Email:
derrick_wong@hq.a-star.edu.sg
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2024 to May 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From May 2023 to May 2024